Enthera Overview
- Year Founded
-
2016

- Status
-
Private
- Employees
-
16

- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$42.6M
- Investors
-
10
Enthera General Information
Description
Developer of biotherapeutics intended to treat auto-immune disorders. The company's pipelined products target pathways involved in cell apoptosis in the gut, pancreas, and other organs which plays a key role in the development of type 1 diabetes and inflammatory bowel disease, enabling the medical community to effectively combat intractable autoimmune diseases.
Contact Information
Website
www.entherapharmaceuticals.comCorporate Office
- Via Visconti di Modrone, 18
- 20122 Milan(Lombardy)
- Italy
Corporate Office
- Via Visconti di Modrone, 18
- 20122 Milan(Lombardy)
- Italy
Enthera Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Later Stage VC (Series A) | 28-Jan-2021 | $42.6M | Completed | Clinical Trials - Phase 1 | ||
3. Seed Round | 24-Jul-2018 | Completed | Pre-Clinical Trials | |||
2. Early Stage VC | 10-May-2018 | Completed | Pre-Clinical Trials | |||
1. Seed Round | 01-Oct-2016 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Enthera Comparisons
Industry
Financing
Details
Enthera Competitors (28)
One of Enthera’s 28 competitors is AnTolRx, a Formerly VC-backed company based in Cambridge, MA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
Equillium | Formerly VC-backed | La Jolla, CA | ||||
Mitobridge | Formerly VC-backed | Cambridge, MA | ||||
Stealth BioTherapeutics | Private Equity-Backed | Needham, MA | ||||
Metabolic Solutions Development Company | Venture Capital-Backed | Kalamazoo, MI |
Enthera Patents
Enthera Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-4537907-A1 | Cd248 inhibitors and uses thereof | Pending | 10-Oct-2023 | ||
CA-3162043-A1 | Antibody inhibitors of igfbp5 | Pending | 20-Feb-2020 | ||
AU-2021225061-A1 | Inhibitors and uses thereof | Inactive | 20-Feb-2020 | ||
EP-3868396-A1 | Inhibitors and uses thereof | Inactive | 20-Feb-2020 | ||
EP-4106804-A1 | Inhibitors and uses thereof | Pending | 20-Feb-2020 | C07K16/18 |
Enthera Signals
Enthera Investors (10)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
AbbVie Ventures | Corporate Venture Capital | Minority | ||
Banca Profilo | Asset Manager | Minority | ||
Banor Sim | Family Office | Minority | ||
Landmark Capital (Italy) | Family Office | Minority | ||
Roche Venture Fund | Corporate Venture Capital | Minority |
Enthera FAQs
-
When was Enthera founded?
Enthera was founded in 2016.
-
Where is Enthera headquartered?
Enthera is headquartered in Milan, Italy.
-
What is the size of Enthera?
Enthera has 16 total employees.
-
What industry is Enthera in?
Enthera’s primary industry is Drug Discovery.
-
Is Enthera a private or public company?
Enthera is a Private company.
-
What is Enthera’s current revenue?
The current revenue for Enthera is
. -
How much funding has Enthera raised over time?
Enthera has raised $47.2M.
-
Who are Enthera’s investors?
AbbVie Ventures, Banca Profilo, Banor Sim, Landmark Capital (Italy), and Roche Venture Fund are 5 of 10 investors who have invested in Enthera.
-
Who are Enthera’s competitors?
AnTolRx, Equillium, Mitobridge, Stealth BioTherapeutics, and Metabolic Solutions Development Company are some of the 28 competitors of Enthera.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »